The precipitous cancellation of Australia’s Economic Accelerator (AEA) this month, alongside the redirection of $800 million in uncommitted funding, has sent a shock wave through their research, science and technology sector.
Touted as “one to watch” in biotech investor circles, German biopharmaceutical company Kupando is advancing a disruptive dual approach that could both reduce solid tumours and counter infectious diseases.
Paris based company Standing Ovation specialises in producing animal-free casein through precision fermentation. They just raised an impressive €30 million as part of French efforts to preserve technical sovereignty and secure future food supply.
UK-Portugal greentech venture Arborea is bridging the gap between design engineering and biotechnology with a synthetic leaf that creates food directly from sunlight.
A spinoff company from the Australian National University plans to shake up the garment industry through enzymatic recycling of polyester.
EU Inc, a new pan-European legal entity structure, proposed by the European Commission, aims to simplify company incorporation, investment and acquisitions for startup ventures across the European Union.
New Zealand deep tech startup Wellumio is developing a portable NMR scanner that delivers quicker patient care and better outcomes.
A Swedish biotech startup is making waves in the field of 3D “spatial biology” for transcriptomics – a game changer for accelerated development of drug therapies.
Copenhagen. A city of contradictions. Where fairy-tale whimsy and comfort foods like ice-cream and pølser converge with a gritty maritime history, or where the cosy warmth of indoor pubs contrasts with showery weather blowing in from adjacent seas. But the Danish capital is now forging a new path as the centre of gravity for European…
